We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+1.32%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.45B
AUM Growth
-$11.8M
Cap. Flow
-$571K
Cap. Flow %
-0.02%
Top 10 Hldgs %
40.31%
Holding
207
New
13
Increased
45
Reduced
58
Closed
10

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$8.47M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.05M
3
ISRG icon
Intuitive Surgical
ISRG
+$7.91M
4
BSX icon
Boston Scientific
BSX
+$6.1M
5
GILD icon
Gilead Sciences
GILD
+$5.71M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$20.7M
2
ILMN icon
Illumina
ILMN
+$12.7M
3
ELV icon
Elevance Health
ELV
+$10.4M
4
CNC icon
Centene
CNC
+$6.81M
5
AGN
Allergan plc
AGN
+$6.78M

Sector Composition

Rank Sector Weight
1 Healthcare 95.11%
2 Real Estate 2.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
151
Madrigal Pharmaceuticals
MDGL
$10.8B
$1.4M 0.06%
13,340
– –
EVH icon
152
Evolent Health
EVH
$348M
$1.39M 0.06%
174,270
+132,120
+313% +$1.56M
MIST icon
153
Milestone Pharmaceuticals
MIST
$138M
$1.36M 0.06%
+50,000
New +$1.03M
CNCE
154
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$1.33M 0.05%
110,853
+65,491
+144% +$704K
DPLO
155
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$1.31M 0.05%
214,845
– –
SGMO
156
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.3M 0.05%
120,768
-120,770
-50% -$1.28M
HR icon
157
Healthcare Realty
HR
$7.28B
$1.26M 0.05%
46,000
– –
MTEM
158
DELISTED
Molecular Templates, Inc.
MTEM
$1.2M 0.05%
9,607
– –
EDIT icon
159
Editas Medicine
EDIT
$396M
$1.11M 0.05%
44,989
-31,679
-41% -$756K
SNR
160
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$1.06M 0.04%
158,047
-105,600
-40% -$649K
ALLK
161
DELISTED
Allakos
ALLK
$1.06M 0.04%
24,414
– –
PRGO icon
162
Perrigo
PRGO
$1.4B
$1.03M 0.04%
21,718
– –
SPPI
163
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$987K 0.04%
114,670
– –
MOR
164
DELISTED
MorphoSys AG American Depositary Shares
MOR
$957K 0.04%
+39,643
New +$983K
ACIU icon
165
AC Immune
ACIU
$223M
$954K 0.04%
171,813
– –
VKTX icon
166
Viking Therapeutics
VKTX
$3.7B
$946K 0.04%
114,016
– –
INGN icon
167
Inogen
INGN
$175M
$935K 0.04%
14,000
+6,000
+75% +$457K
ADAP
168
DELISTED
Adaptimmune Therapeutics
ADAP
$919K 0.04%
228,496
– –
PBYI icon
169
Puma Biotechnology
PBYI
$404M
$907K 0.04%
71,340
– –
ARWR icon
170
Arrowhead Research
ARWR
$11.9B
$814K 0.03%
30,700
– –
XRN
171
Chiron Real Estate Inc
XRN
$514M
$771K 0.03%
14,680
– –
AFMD
172
DELISTED
Affimed
AFMD
$729K 0.03%
25,400
– –
FOMX
173
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$716K 0.03%
300,781
– –
ITCI
174
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$715K 0.03%
55,096
-55,097
-50% -$707K
OVID icon
175
Ovid Therapeutics
OVID
$414M
$690K 0.03%
372,733
-124,244
-25% -$222K
5 6
7
8 9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Tekla Capital Management held 207 positions worth $2.45B, down 0.48% from $2.46B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q2 2019 filing shows 13 new, 45 increased, 58 reduced and 10 closed positions. Its largest new stake was Alcon: 55,369 shares worth $3.44M. The largest sale was Biogen, an estimated $20.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2019 buy was Alcon: 55,369 shares worth $3.44M.
  • Tekla Capital Management added most to Regeneron Pharmaceuticals in Q2 2019, an estimated $8.47M increase.
  • Tekla Capital Management's biggest Q2 2019 reduction was Biogen, cutting an estimated $20.7M.
  • Tekla Capital Management fully exited Centene in Q2 2019, selling an estimated $6.81M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.45B portfolio in Q2 2019.
  • Tekla Capital Management opened 13 new positions and closed 10 in Q2 2019.
  • Tekla Capital Management's portfolio value fell 0.48% quarter-over-quarter to $2.45B.

Based on Tekla Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.